Andere talen Bristol-Myers Squibb Company Swiss Exchange

Aandelen

BMY

US1101221083

Beurs gesloten - Swiss Exchange Andere beurzen 05:55:00 03-07-2019			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
45,3 ^USD	-0,90%		-.--%	-.--%

04/06	Bristol-Myers Squibb zegt dat Opdivo plus Yervoy-therapie de overleving van leverkankerpatiënten verbetert	MT
03/06	Bristol-Myers Squibb zegt dat Breyanzi-studies 'betekenisvolle' resultaten laten zien bij B-cel maligniteiten	MT

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

Bristol-Myers Squibb Says Opdivo Plus Yervoy Therapy Improves Survival of Liver Cancer Patients	04/06
Bristol Myers : résultats positifs dans le cancer du foie	04/06
Bristol Myers Squibb Announces Opdivo (nivolumab) Plus Yervoy (ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carcinoma in CheckMate -9DW Trial	04/06
Bristol Myers Squibb to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference	04/06
Bristol-Myers Squibb Says Breyanzi Studies Show 'Meaningful' Outcomes Across B-cell Malignancies	03/06
Bristol Myers Squibb’s Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented at 2024 ASCO® Annual Meeting	03/06
Bristol Myers Squibb?S Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented At 2024 Asco® Annual Meeting	03/06
Bristol Myers : présente ses avancées en cancer du poumon	03/06
Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO® Annual Meeting Highlighting Opdivo and Opdivo-based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer	03/06
Bristol Myers Squibb Presents Multiple New Analyses At 2024 Asco® Annual Meeting Highlighting Opdivo and Opdivo-Based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer	03/06
Pre-surgery treatment with Bristol Myers combination therapy leads to better skin cancer outcomes	02/06
GSK blood cancer drug nearly halves risk of death in late-stage trial	02/06
KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Cancer	01/06
Bristol Myers Squibb Announces Results from the Phase 3 KRYSTAL-12 Study Evaluating KRAZATI®?	01/06
Bristol-Myers Squibb Says Breyanzi Gets FDA Approval as CAR T Cell Therapy for Mantle Cell Lymphoma	30/05
Bristol Myers : approbation de la FDA pour Breyanzi	30/05
US FDA allows use of Bristol's cell therapy for rare blood cancer	30/05
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma	30/05
U.S. Food and Drug Administration Approves Bristol Myers Squibb?s Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma	30/05
Bristol Myers Squibb’s Urothelial Carcinoma Combo Drug Gets EU Commission Approval	29/05

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Headlines

Bristol-Myers CEO zegt dat het bedrijf in overgang is

09 januari 2024 om 19:06 uur